BioSpace News Archive

GC Biopharma, a South Korean biopharmaceutical company, announced on the 18th that its quadrivalent flu vaccine called GC FLU Quadrivalent Pre-filled syringe inj.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its second quarter 2023 financial results on Tuesday, August 8th, 2023 at 7:30 a.m. Pacific Time.

Enzolytics, Inc. announced today a partnership with Khalpey AI Lab to identify biomarkers for early onset Alzheimer’s disease.

UCB, a global biopharmaceutical company, today announced that RYSTIGGO is commercially available for the treatment of adult patients in the U.S. with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged six months or older.

Fresh Tracks Therapeutics, Inc. announced it has entered into an amendment to its Asset Purchase Agreement with Botanix Pharmaceuticals Limited and its subsidiary, Botanix SB Inc., to sell its rights to future event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. for $8.25 million.

Genetic Technologies Limited advises that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

AcelRx Pharmaceuticals, Inc. today announced the closing of its previously announced private placement of common stock, pre-funded warrants and common warrants for aggregate gross proceeds to the Company of $10 million.

Biotricity, Inc. today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing Biotricity that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of JZP458.